186 related articles for article (PubMed ID: 24521156)
1. Computational inhibition studies of the human proteasome by argyrin-based analogues with subunit specificity.
Loizidou EZ; Zeinalipour-Yazdi CD
Chem Biol Drug Des; 2014 Jul; 84(1):99-107. PubMed ID: 24521156
[TBL] [Abstract][Full Text] [Related]
2. Modulation of proteasome subunit selectivity of syringolins.
Tatsumi K; Kitahata S; Komatani Y; Katsuyama A; Yakushiji F; Ichikawa S
Bioorg Med Chem; 2024 May; 106():117733. PubMed ID: 38704960
[TBL] [Abstract][Full Text] [Related]
3. Blockade of the malignant phenotype by β-subunit selective noncovalent inhibition of immuno- and constitutive proteasomes.
Villoutreix BO; Khatib AM; Cheng Y; Miteva MA; Maréchal X; Vidal J; Reboud-Ravaux M
Oncotarget; 2017 Feb; 8(6):10437-10449. PubMed ID: 28060729
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a potent and highly specific β
Zhou T; Cai Y; Liang L; Yang L; Xu F; Niu Y; Wang C; Zhang JL; Xu P
Bioorg Med Chem Lett; 2016 Dec; 26(23):5780-5784. PubMed ID: 27816516
[TBL] [Abstract][Full Text] [Related]
5. Systematic Analyses of Substrate Preferences of 20S Proteasomes Using Peptidic Epoxyketone Inhibitors.
Huber EM; de Bruin G; Heinemeyer W; Paniagua Soriano G; Overkleeft HS; Groll M
J Am Chem Soc; 2015 Jun; 137(24):7835-42. PubMed ID: 26020686
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes.
de Bruin G; Huber EM; Xin BT; van Rooden EJ; Al-Ayed K; Kim KB; Kisselev AF; Driessen C; van der Stelt M; van der Marel GA; Groll M; Overkleeft HS
J Med Chem; 2014 Jul; 57(14):6197-209. PubMed ID: 25006746
[TBL] [Abstract][Full Text] [Related]
7. Dimerized linear mimics of a natural cyclopeptide (TMC-95A) are potent noncovalent inhibitors of the eukaryotic 20S proteasome.
Desvergne A; Genin E; Maréchal X; Gallastegui N; Dufau L; Richy N; Groll M; Vidal J; Reboud-Ravaux M
J Med Chem; 2013 Apr; 56(8):3367-78. PubMed ID: 23540790
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, and Biological Activity of Isosyringolin A.
Kitahata S; Chiba T; Yoshida T; Ri M; Iida S; Matsuda A; Ichikawa S
Org Lett; 2016 May; 18(9):2312-5. PubMed ID: 27123978
[TBL] [Abstract][Full Text] [Related]
9. Argyrin B, a non-competitive inhibitor of the human immunoproteasome exhibiting preference for β1i.
Allardyce DJ; Bell CM; Loizidou EZ
Chem Biol Drug Des; 2019 Aug; 94(2):1556-1567. PubMed ID: 31074944
[TBL] [Abstract][Full Text] [Related]
10. Proteasome activity imaging and profiling characterizes bacterial effector syringolin A.
Kolodziejek I; Misas-Villamil JC; Kaschani F; Clerc J; Gu C; Krahn D; Niessen S; Verdoes M; Willems LI; Overkleeft HS; Kaiser M; van der Hoorn RA
Plant Physiol; 2011 Jan; 155(1):477-89. PubMed ID: 21045122
[TBL] [Abstract][Full Text] [Related]
11. Development of peptidomimetic boronates as proteasome inhibitors.
Micale N; Ettari R; Lavecchia A; Di Giovanni C; Scarbaci K; Troiano V; Grasso S; Novellino E; Schirmeister T; Zappalà M
Eur J Med Chem; 2013 Jun; 64():23-34. PubMed ID: 23639651
[TBL] [Abstract][Full Text] [Related]
12. Structure- and function-based design of Plasmodium-selective proteasome inhibitors.
Li H; O'Donoghue AJ; van der Linden WA; Xie SC; Yoo E; Foe IT; Tilley L; Craik CS; da Fonseca PC; Bogyo M
Nature; 2016 Feb; 530(7589):233-6. PubMed ID: 26863983
[TBL] [Abstract][Full Text] [Related]
13. Activity enhancement of the synthetic syrbactin proteasome inhibitor hybrid and biological evaluation in tumor cells.
Archer CR; Groll M; Stein ML; Schellenberg B; Clerc J; Kaiser M; Kondratyuk TP; Pezzuto JM; Dudler R; Bachmann AS
Biochemistry; 2012 Aug; 51(34):6880-8. PubMed ID: 22870914
[TBL] [Abstract][Full Text] [Related]
14. Peptido sulfonyl fluorides as new powerful proteasome inhibitors.
Brouwer AJ; Jonker A; Werkhoven P; Kuo E; Li N; Gallastegui N; Kemmink J; Florea BI; Groll M; Overkleeft HS; Liskamp RM
J Med Chem; 2012 Dec; 55(24):10995-1003. PubMed ID: 23170994
[TBL] [Abstract][Full Text] [Related]
15. α-Keto phenylamides as P1'-extended proteasome inhibitors.
Voss C; Scholz C; Knorr S; Beck P; Stein ML; Zall A; Kuckelkorn U; Kloetzel PM; Groll M; Hamacher K; Schmidt B
ChemMedChem; 2014 Nov; 9(11):2557-64. PubMed ID: 25087721
[TBL] [Abstract][Full Text] [Related]
16. Noncovalent inhibitors of human 20S and 26S proteasome based on trypsin inhibitor SFTI-1.
Dębowski D; Cichorek M; Lubos M; Wójcik S; Łęgowska A; Rolka K
Biopolymers; 2016 Sep; 106(5):685-96. PubMed ID: 27258473
[TBL] [Abstract][Full Text] [Related]
17. Phenoxypropanolamine derivatives as selective inhibitors of the 20S proteasome β1 and β5 subunits.
Hovhannisyan AA; Pham TH; Bouvier D; Tan X; Touhar S; Mkryan GG; Dallakyan AM; El Amri C; Melikyan GS; Reboud-Ravaux M; Bouvier-Durand M
Bioorg Med Chem Lett; 2017 Dec; 27(23):5172-5178. PubMed ID: 29113763
[TBL] [Abstract][Full Text] [Related]
18. Insight into Inhibitor Binding in the Eukaryotic Proteasome: Computations of the 20S CP.
Hodošček M; Elghobashi-Meinhardt N
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30514002
[TBL] [Abstract][Full Text] [Related]
19. Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors.
Troiano V; Scarbaci K; Ettari R; Micale N; Cerchia C; Pinto A; Schirmeister T; Novellino E; Grasso S; Lavecchia A; Zappalà M
Eur J Med Chem; 2014 Aug; 83():1-14. PubMed ID: 24946214
[TBL] [Abstract][Full Text] [Related]
20. C-terminal trans,trans-muconic acid ethyl ester partial retro-inverso pseudopeptides as proteasome inhibitors.
Franceschini C; Trapella C; Calia R; Scotti A; Sforza F; Gavioli R; Marastoni M
J Enzyme Inhib Med Chem; 2013 Oct; 28(5):1034-9. PubMed ID: 22871133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
